Related Experiment Video

Updated: Aug 16, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Neonatal diabetes mellitus: Insulin pump as an alternative management strategy

Tara Bharucha1, Justin Brown, Ciara McDonnell

  • 1Centre for Hormone Research, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

Journal of Paediatrics and Child Health
|September 10, 2005
PubMed

Insights

Neonatal diabetes mellitus, a condition requiring insulin in newborns, presents management challenges. Subcutaneous insulin pump therapy offers a successful alternative to conventional methods for treating this complex condition.

Area of Science:

  • Neonatology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Neonatal diabetes mellitus (NDM) is hyperglycemia presenting within the first month of life, necessitating insulin therapy.
  • Management of NDM is complex due to infants' limited subcutaneous fat and requirement for precise, small insulin doses.
  • NDM can be transient or permanent, often co-occurring with other medical issues.

Observation:

  • Three cases of neonatal diabetes mellitus were analyzed.
  • The first case was managed with conventional insulin therapy.
  • The subsequent two cases demonstrated successful treatment outcomes using subcutaneous insulin pump therapy.

Findings:

  • Subcutaneous insulin pump therapy proved effective in managing neonatal diabetes mellitus in two cases.
  • This approach addresses challenges related to small insulin dosages and limited subcutaneous fat in neonates.
  • Conventional insulin therapy was used in one case, providing a comparison.

Implications:

  • Subcutaneous insulin pump therapy represents a novel and effective approach for managing neonatal diabetes mellitus.
  • Guidelines for utilizing insulin pump therapy in neonates with diabetes are proposed.
  • This innovative management strategy may improve outcomes for infants with NDM.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...